Earnings summaries and quarterly performance for PMV Pharmaceuticals.
Executive leadership at PMV Pharmaceuticals.
Board of directors at PMV Pharmaceuticals.
Research analysts covering PMV Pharmaceuticals.
Recent press releases and 8-K filings for PMVP.
PMV Pharmaceuticals Reports Q3 2025 Financial Results and Positive Clinical Data
PMVP
Earnings
Guidance Update
New Projects/Investments
- PMV Pharmaceuticals, Inc. reported $129.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing an expected cash runway to the end of the first quarter of 2027.
- The company announced updated clinical results from the Phase 2 pivotal portion of the PYNNACLE study for rezatapopt, observing a 34% overall response rate (ORR) among 103 evaluable patients across all cohorts, with a median duration of response of 7.6 months.
- In the ovarian cancer cohort, a 46% ORR was observed among 48 evaluable patients, with a median duration of response of 8.0 months.
- PMV Pharma plans to submit a New Drug Application (NDA) for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
Nov 12, 2025, 1:00 PM
PMV Pharmaceuticals Announces Updated Rezatapopt Phase 2 Clinical Trial Data
PMVP
New Projects/Investments
Product Launch
- PMV Pharmaceuticals reported updated interim data from its Phase 2 PYNNACLE clinical trial for rezatapopt, showing a 34% overall response rate (ORR) among 103 evaluable patients across all cohorts, with a median duration of response of 7.6 months.
- In the ovarian cancer cohort, rezatapopt achieved a 46% ORR among 48 evaluable patients, with a median duration of response of 8.0 months.
- The company plans to submit a New Drug Application (NDA) for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
- Treatment-related adverse events were mostly Grade 1-2, with a drug discontinuation rate of 3.6% due to TRAEs.
Oct 24, 2025, 3:39 PM
PMV Pharmaceuticals Provides Update on Rezatapopt Clinical Program and Financial Outlook
PMVP
New Projects/Investments
Guidance Update
- PMV Pharmaceuticals (PMVP) reported that its clinical candidate, rezatapopt, achieved a 38% Overall Response Rate (ORR) at the recommended Phase II dose of 2,000 mg q.d. in its Phase I trial.
- An interim analysis for the single-arm registrational Phase II trial of rezatapopt is expected in the middle of 2025, with the company targeting an NDA submission by the end of 2026.
- The company ended 2024 with a cash balance of $183 million, which is expected to fund operations through the end of 2026.
- PMV Pharmaceuticals has also initiated a Phase Ib combination study of rezatapopt in AML and anticipates announcing a development candidate for an undisclosed target in mid-2025.
Mar 4, 2025, 8:10 PM
PMV Pharmaceuticals Provides Update on Rezatapopt Phase II Trial and Financial Runway
PMVP
Guidance Update
New Projects/Investments
- PMV Pharmaceuticals had planned an interim analysis in mid-2025 for its pivotal Phase II trial of rezatapopt, a p53 reactivator, which was to include a minimum of 30 patients and 18 weeks of follow-up.
- The company aims to submit a New Drug Application (NDA) for rezatapopt by the end of 2026, targeting an accelerated approval strategy based on a 30% overall response rate and six months median durability of response.
- PMV Pharmaceuticals reported a cash balance of $183 million at the end of 2024, which is projected to fund operations through the end of 2026.
- The Phase II study is a basket study of 114 patients with TP53 Y220C and KRAS wild-type solid tumors, with 42 patients in ovarian cancer and 18 patients each in lung, breast, endometrial, and other solid tumor cohorts.
- PMV had also planned to provide information on a new, undisclosed, orally administered, non-covalent development candidate for solid tumors, orthogonally connected to p53, in mid-2025, with an IND submission targeted for H1 2026.
Mar 4, 2025, 8:10 PM
PMV Pharma Provides Update on Rezatapopt Phase 2 Trial and Pipeline Development
PMVP
New Projects/Investments
Guidance Update
- PMV Pharma's lead product, Rezatapopt, is in a phase two registrational trial for mutant p53s, with interim data expected mid-2025. The company plans to share data from at least 30 patients with 18 weeks of follow-up across all study cohorts.
- The phase two study is designed to target a 30% overall response rate (ORR), building on phase one data that showed a 38% confirmed ORR at 2,000 mg QD with food, including a 47% response rate in ovarian cancer and a seven-month median duration of response.
- An initial NDA submission for Rezatapopt, likely starting with ovarian cancer, is anticipated by the end of 2026.
- The company reported $198 million in cash at the end of the third quarter (last year), providing a runway through the end of 2026, and is exploring options to raise additional capital.
- PMV Pharma plans to announce a new program in the development candidate phase in Q2 2025, with IND-enabling studies to follow and a potential first-in-human trial in 2026 for a target related to the p53 pathway.
Feb 12, 2025, 5:40 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more